Edwards Lifesciences Corp (EW) has garnered significant attention in the recent times due to its pivotal role in the biotech market. The valuation of the corporation has oscillated owing to its numerous highs and lows. EW exhibited a strong growth in medical devices sales, particularly in the shipment of
TAVR to severe AS patients in Q2 of 2025. The company also executed an
$500M accelerated share buyback. Several investment powerhouses including
Citadel Investment Group have perceived EW as one of the top stocks to purchase, while on the flip side, FTC has stepped in proposing to halt EW's acquisition of
JenaValve. The 2025 Q2 earnings, although beating revenue expectations, showed a dip in EPS prompting a mix of responses from investors. Encouragingly, quarterly earnings from Q1 and Q4 of 2024 witnessed robust full-year growth and beat EPS estimates. Pioneering trials like the
TRISCEND II and ENCIRCLE also give hope for potential advancements in valve treatments. However, amidst this positive outlook, EW stock experienced some pressure and fell by 1.58% in the premarket.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Oct 2024 07:00:00 GMT to Sat, 30 Aug 2025 19:43:07 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -3
